Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 47, Issue 6, 2005, Pages 327-331

  Taylor Castillo, Lizeth ^a,e   Herrera Martínez, Gisela ^b   León Bratti, María Paz ^c   Boza, Ricardo ^d   León Rodríguez, Bernal ^a   Luftig, Ronald B ^a   Visoná, Kirsten ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Hospital Calderon Guardia   (Costa Rica)

^c Hosp Mexico   (Costa Rica)

^d San Juan de Dios Hospital   (Costa Rica)

^e UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

Adherence; Anti retroviral treatment; Highly active antiretroviral therapy; Human immunodeficiency virus; Resistance mutations; Response; Risk factors

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COSTA RICA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUESTIONNAIRE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS MUTANT; VIRUS STRAIN;

EID: 31544475674     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/s0036-46652005000600004     Document Type: Article

References (32)

1. ALEXANDER, C.S; ASSELIN, J.J.; TING, L.S. et al. - Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J. infect. Dis., 188: 541-548, 2003.
2. CASCADE COLLABORATION - Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet, 262: 1267-1274, 2003.
3. CLEVENBERGH, P.; DURANT, J.; CHAILLOU, S. & DELLAMONICA, P. - HIV drug resistance and insufficient drug plasma levels as factor determining antiretroviral treatment failure. AIDS Rev., 1: 1576, 1999.
4. DEEKS, S.G. - Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet, 362: 2002-2011, 2002.
5. DRAGSTED, U.B.; GERSTOFT, J.; PEDERSEN, C. et al. - Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. J. infect. Dis., 188: 635-642, 2003.
6. ERALI, M.; PAGE, S.; REIMER, L. & HILLYARD, D.R. - Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J. clin. Microbiol., 39: 2157-2165, 2001.
7. GALLEGO, O.; RUIZ, L.; VALLEJO, A. et al. - Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjets on antiretroviral therapy in Spain. J. clin. Microbiol., 40: 3865-3866, 2002.
8. GALLI, R.A.; SATTHA, B.; WYNHOVEN, B.; O' SHAUGHNESSY, M.V. & HARRIGAN, P.R. - Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance. J. clin. Microbiol., 41: 2900-2907, 2003.
9. GAZZARD, B.; MOYLE, G.; WEBER, J. et al. - British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Coordinating Committee. Lancet, 349: 1086-1092, 1997.
10. GRANT, R.M.; KURITZKES, D.R.; JOHNSON, V.A. et al. - Accuracy of TRUGENE HIV-1 genotyping kit. J. clin. Microbiol., 41: 1586-1593, 2003.
11. HAMMER, S.M.; TÜRMEN, T.; VARELDZIZ, B. & PERRIENS, J. - Antiretroviral guidelines for resource-limited settings: the WHO's public health approach. Nature Med., 8: 649-650, 2002.
12. HUANG, D.D.; ESHLEMAN, S.H.; BRANBILLA, D.J.; PALUMBO, P.E. & BRENER, J.W. - Evaluation of the editing process in human immunodeficiency virus type I genotyping. J. clin. Microbiol., 41: 3265-3272, 2003.
13. JIANG, H.; DEEKS, S.G.; KURITZKES, D.R. et al. - Assessing resistance cost of antiretroviral therapies via measures of future drugs options. J. infect. Dis., 188: 1001-1008, 2003.
14. KURITZKES, D.R.; GRANT, R.M.; FEORINO, P. et al. - Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene sequencing system. J. clin. Microbiol., 41: 1594-1599, 2003.
15. LEDERGERBER, B.; EGGER, M.; OPRAVIL, M. et al. - Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet, 353: 863-868, 1998.
16. LEE, N.; HOGG, R.S.; YIP, B.; HARRIGAN, P.R. et al. - Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J. infect. Dis., 188: 137-141, 2003.
17. LITTLE, S.J.; HOLTE, S.; ROUTY, J.P. et al. - Antiretroviral drugs resistance among patients recently infected with HIV. New Engl. J. Med., 347: 385-394, 2002.
18. MEMBERS. AOL.COM/MJAYM/NEWS.HTML - Commonality news.
19. MOATTI, J.P.; N'DOYE, I.; HAMMER, S.M.; HALE, P. & KAZATCHKINE, M. - Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nature Med., 9: 1449-1452, 2003.
20. PERNO, C.L.; COZZI-LEPRI, A.; FORBICI, F. et al. - Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed. J. infect. Dis., 189: 1983-1987, 2004.
21. PIRES, L.I.; SOARES, M.A.; SPERANZA, F.A. et al. - Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil. J. clin. Microbiol., 42: 426-430, 2004.
22. RIZZARDI, G.P.; DE BOER, R.J.; HOOVER, S. et al. - Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J. clin. Invest., 105: 777-782, 2000.
23. SERVAIS, J.; LAMBERT, C.; FONTAINE, E. et al. - Comparison of DNA sequencing and line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J. clin. Microbiol., 39: 454-459, 2001.
24. SVEDHEM, V.; LINDKVIST, A.; LIDMAN, K. & SONNERBORG, A. - Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. J. med. Virol., 68: 473-478, 2002.
25. TORTI, C.; QUIROS-ROLDAN, E.; KEULEN, W. et al. - Comparison between rules-based human immunodeficiency virus type I genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J. infect. Dis., 188: 194-201, 2003.
26. VAN VAERENBERGH, K.; VAN LAETHEM, K.; ALBERT, J. et al. - Prevalence and characteristic of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combination of nucleoside analogues. Antimicrob. Agents Chemother., 44: 2109-2117, 2000.
27. WEINSTOCK, H.S.; ZAIDI, I.; HENEINE, W. et al. - The epidemiology of antiretroviral drug resistance among drug-naive HIV-1 infected persons in 10 US cities. J. infect. Dis., 189: 2174-2180, 2004.
28. WINTERS, M.A.; BOSCH, R.J.; ALBRECHT, M.A.; KATZENSTEIN, D.A. & AIDS CLINICAL TRIALS GROUP 364 STUDY TEAM - Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment nucleoside reverse-transcriptase inhibitor-experienced patients. J. infect. Dis., 188: 537-540, 2003.
29. WHITCOMB, J.M.; PARKIN, N.T.; CHAPPEY, C.; HELLMAN, N.S. & PETROPOULOS, C.J. - Broad nucleoside reverse-transcriptase inhibitor crossresistance in human immunodeficiency virus type I clinical isolates. J. infect. Dis., 188: 992-1000, 2003.
30. WWW.ACRIA.ORG/TREATMENT/TREATMENT_EDU_DRUG_RESIST.HTML - What are some of the factors that contribute to the accumulation of drug-resistance mutations during therapy?
31. WWW.PROJINF.ORG/WHATSNEWS/WN_9808.HTML - Project Inform's What's new? Memo August 1998 (HIV/AIDS Treatment Information).
32. WWW.THEBODY.COM/PINF/ESPANOL/DRUGID_SP.HTML - The body: Proyecto inform: cuadro de identificación de medicamentos.